Drugs

, Volume 61, Issue 10, pp 1379–1385 | Cite as

New and Emerging Therapies for Pulmonary Complications of Cystic Fibrosis

Leading Article

Abstract

In the decade since the gene for cystic fibrosis (CF) was discovered, research into potential therapeutic interventions has progressed on a number of different fronts. The vast majority of morbidity and mortality in CF results from inflammation and infection of the airways. Direct delivery of antibacterials to the airway secretions via a nebuliser is an attractive therapeutic option, and a novel formulation of tobramycin designed for such a purpose has been demonstrated to improve spirometry and decrease the need for intravenous antibacterials. In addition, early clinical trials are studying the effects of small peptides with antibiotic properties (defensins) delivered directly to the airways.

Inflammation, whether secondary to infection or an independent feature of CF, leads to progressive bronchiectasis. Anti-inflammatories such as prednisone and possibly ibuprofen have been shown to decrease the rate of respiratory decline in patients with CF but have tolerability profiles that limit clinical usefulness. Macrolides also have anti-inflammatory properties and clinical trials are now ongoing to assess the efficacy of these agents in CF.

Multiple agents, including uridine triphosphate (UTP), genistein, phenylbutyrate and CPX (cyclopentyl dipropylxanthine), have been demonstrated in cell culture to at least partially correct the primary defect of ion transport related to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). No agent of this class has yet demonstrated clinical effectiveness, but several are in preclinical and early clinical trials.

Finally, gene therapy that allows for the incorporation and expression of wild-type CFTR in respiratory epithelial cells would be definitive therapy for CF. However, multiple barriers to delivery and expression need to be overcome. With research proceeding on these multiple fronts, new therapies for pulmonary complications romise to continue to increase the life expectancy of individuals with CF.

Keywords

Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator Colistin Early Clinical Trial Pulmonary Exacerbation 

Notes

Acknowledgements

Dr Aitken received research funding from targeted Genetics Corporation, Seattle.

References

  1. 1.
    FitzSimmons S. Cystic Fibrosis Foundation Patient Registry Annual Data Report. Bethesda (MD): Cystic Fibrosis Foundation; 1998Google Scholar
  2. 2.
    Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996; 18(335): 179–88Google Scholar
  3. 3.
    Aitken M. Cystic fibrosis. In: Bone R, Petty T, editors. Year book of pulmonary disease, 1996. St. Louis: Mosby, 1996: 155–8Google Scholar
  4. 4.
    Ramsey B, Pepe M, Quan J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl JMed 1999; 340: 23–30CrossRefGoogle Scholar
  5. 5.
    Burns J, Van Dalfsen J, Shawar R, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179: 1190–6PubMedCrossRefGoogle Scholar
  6. 6.
    Hodson M, Penreth A, Batten J. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981: 1137–9Google Scholar
  7. 7.
    Dodd M, Abbott J, Maddison J, et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997; 52: 656–8PubMedCrossRefGoogle Scholar
  8. 8.
    Jensen T, Pedersen S, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987; 19: 831–8PubMedCrossRefGoogle Scholar
  9. 9.
    Bauldoff G, Nunley D, Manzetti J, et al. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997; 64: 748–52PubMedCrossRefGoogle Scholar
  10. 10.
    Smith J, Travis S, Greenberg E, et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal surface fluid. Cell 1996; 85: 229–36PubMedCrossRefGoogle Scholar
  11. 11.
    Konstan M, Berger M. Current understanding of the inflammatory process in cystic fibrosis. Pediatr Pulmonol 1997; 24: 137–42PubMedCrossRefGoogle Scholar
  12. 12.
    Fujii T, Kadota J, Kawakami K, et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50: 1246–52PubMedCrossRefGoogle Scholar
  13. 13.
    Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991; 87: 245–6PubMedGoogle Scholar
  14. 14.
    Eigen H, Rosenstein B, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126: 515–23PubMedCrossRefGoogle Scholar
  15. 15.
    Oermann C, Sockrider M, Konstan M. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999; 115: 1053–8PubMedCrossRefGoogle Scholar
  16. 16.
    Dezateux C, Walters S, Balfour-Lynn I. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2000; 2Google Scholar
  17. 17.
    Konstan M, Byard P, Hoppel C, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848–54PubMedCrossRefGoogle Scholar
  18. 18.
    Kovesi T, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside. N Engl J Med 1998; 338: 65–6PubMedCrossRefGoogle Scholar
  19. 19.
    Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2000; 2Google Scholar
  20. 20.
    Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156–63PubMedGoogle Scholar
  21. 21.
    Sugiyama Y, Yanagisawa K, Tominaga S, et al. Effects of long-term administration of erythromycin on cytokine production. Eur Respir J 1999; 14: 1113–6PubMedCrossRefGoogle Scholar
  22. 22.
    Southern K, Barker P, Solis A. Macrolide antibiotics for cystic fibrosis (Cochrane review). Cochrane Database Syst Rev 2000; 3Google Scholar
  23. 23.
    Konstan M, Stern R, Doershuk C. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr 1994; 124: 689–93PubMedCrossRefGoogle Scholar
  24. 24.
    Pryor J, Webber B, Hodson M, et al. The Flutter VRP1 as an adjuct to chest physiotherapy in cystic fibrosis. Respir Med 1994; 88: 677–81PubMedCrossRefGoogle Scholar
  25. 25.
    Arens R, Gozal D, Omlin K, et al. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 1154–7PubMedGoogle Scholar
  26. 26.
    Fuchs H, Borowitz D, Christiansen D, et al. Effect of aerosolized recombinant DNase on exacerbations of respiratory symtoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637–42PubMedCrossRefGoogle Scholar
  27. 27.
    King M, Dasgupta B, Tomkiewicz R, et al. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997; 156: 173–7PubMedGoogle Scholar
  28. 28.
    Robinson M, Hemming A, Regnis J, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52: 900–3PubMedCrossRefGoogle Scholar
  29. 29.
    Eng P, Morton J, Douglass J, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996; 21: 77–83PubMedCrossRefGoogle Scholar
  30. 30.
    Roomans G. Pharmacological treatment of the ion transport defect in cystic fibrosis. Expert Opin Investig Drugs 2001; 10: 1–19PubMedCrossRefGoogle Scholar
  31. 31.
    Andersson C, Roomans G. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial. Eur Respir J 2000; 15: 937–41PubMedCrossRefGoogle Scholar
  32. 32.
    Devor D, Bridges R, Pilewski J. Pharmacological modulation of ion transport across wild-type and DeltaF 508. Am J Physiol Cell Physiol 2000; 279: C461–79PubMedGoogle Scholar
  33. 33.
    Knowles M, Church N, Waltner W, et al. A pilot study of aerosolized amiloride for the treatment of lung disease. N Engl J Med 1990; 322: 1189–94PubMedCrossRefGoogle Scholar
  34. 34.
    Albelda S, Wiewrodt R, Zuckerman J. Gene therapy for lung disease: hype or hope? Ann Intern Med 2000; 132: 649–60PubMedGoogle Scholar
  35. 35.
    Riordan J, Rommens J, Kerem B-S, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066–73PubMedCrossRefGoogle Scholar
  36. 36.
    Crystal R, McElvaney N, Rosenfeld M, et al. Administration of an adenovirus containing the human CFTR CDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42–51PubMedCrossRefGoogle Scholar
  37. 37.
    Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adeonviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333: 823–31PubMedCrossRefGoogle Scholar
  38. 38.
    Zabner J, Ramsey B, Meeker D, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis. J Clin Invest 1996; 97: 1504–11PubMedCrossRefGoogle Scholar
  39. 39.
    Gill D, Southern K, Mofford K, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal. Gene Ther 1997; 4: 199–209PubMedCrossRefGoogle Scholar
  40. 40.
    Hyde S, Southern K, Gileadi U, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients. Gene Ther 2000; 7: 1156–65PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Division of Pulmonary and Critical Care Medicine Department of MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations